ADC Therapeutics SA
NYSE:ADCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ADC Therapeutics SA
NYSE:ADCT
|
CH |
|
J
|
Joong Ang Enervis Co Ltd
KOSDAQ:000440
|
KR |
|
ING Groep NV
F:INN1
|
NL |
|
Nippon Sanso Holdings Corp
OTC:TYNPF
|
JP |
|
Swiss Re AG
SIX:SREN
|
CH |
|
Bureau Veritas SA
PAR:BVI
|
FR |
|
thyssenkrupp AG
MIL:1TKA
|
DE |
|
Aeon Co Ltd
OTC:AONNY
|
JP |
|
G
|
Gibo Holdings Ltd
NASDAQ:GIBO
|
HK |
|
P
|
PTC Therapeutics Inc
XBER:BH3
|
US |
|
M
|
MGIC Investment Corp
XBER:MGC
|
US |
|
A
|
Arcadis NV
LSE:0N6B
|
NL |
|
F
|
Fiserv Inc
XBER:FIV
|
US |
|
S
|
Stryker Corp
F:SYK
|
US |
|
B
|
Boston Scientific Corp
DUS:BSX
|
US |
Wall St Price Targets
ADCT Price Targets Summary
ADC Therapeutics SA
According to Wall Street analysts, the average 1-year price target for
ADCT is 4.85 USD with a low forecast of 0.51 USD and a high forecast of 10.5 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ADCT's stock price target?
Price Target
4.85
USD
According to Wall Street analysts, the average 1-year price target for
ADCT is 4.85 USD with a low forecast of 0.51 USD and a high forecast of 10.5 USD.
What is the Revenue forecast for ADC Therapeutics SA?
Projected CAGR
38%
Over the last 7 years, the compound annual growth rate for Revenue has been 85%. The projected CAGR for the next 3 years is 38%.
What is the Gross Profit forecast for ADC Therapeutics SA?
Projected CAGR
53%
The compound annual growth rate for Gross Profit over the next 3 years is 53%.